Fusion Pharmaceuticals — Corporate Update (March 2021)
12 slides from Fusion Pharmaceuticals's corporate update, Mar 2, 2021
Slide 1: IPN 1087 Acquisition and Fusion's Expanding Pipeline
Exhibit 99.2 IPN 1087 Acquisition and Fusion’s Expanding Pipeline March 2021Exhibit 99.2 IPN 1087 Acquisition and Fusion’s Expanding Pipeline March 2021
Slide 2: Fusion – Next Generation TATs for Precision Oncology
Fusion – Next Generation TATs for Precision Oncology Targeted Alpha Therapies (TATs) deliver radiation directly to cancer PDAC Imaging cells using a precision medicine approach (theranostics) coronal ■ Fusion can create TATs from wide range of targeting molecules (antibodies, proteins, small molecul
Slide 3: Fusion: Built As a Platform Company to Develop Multiple Classes of TATs
Fusion: Built As a Platform Company to Develop Multiple Classes of TATs Internal R&D Expertise Manufacturing and Supply Chain Expertise Ability and Experience Linking Alpha Emitting Isotopes to Radiopharmaceutical Manufacturing Different Classes of Targeting Molecules World-class GMP Manufacturing A
Slide 4: Fusion's Next Generation Radiopharmaceuticals for Precision Oncology
Fusion’s Next Generation Radiopharmaceuticals for Precision Oncology Targeted TAT Binds to TAT Building Alpha the Target Blocks Therapy Tumor Cells (TAT) Actinium-225 Alpha-emitting Isotope Receptor The Chelate Proprietary Targeting Small Molecule As Carrier for Ac-225 4Fusion’s Next Generation Radi
Slide 5: TATs: Multiple Mechanisms of Action
TATs: Multiple Mechanisms of Action Multiple Mechanisms of Action of a TAT TAT Binds to the 1) Multiple lethal 2) Bystander 3) Potential Target Receptor double-stranded effect vaccine effect Tumor Cells Tumor DNA breaks Localized TAT Bystander Primary Cell Death Cell Ac-225 α Death decay Particles C
Slide 6: IPN-1087 - A Validated Targeted Theranostic for NTSR1
IPN-1087 - A Validated Targeted Theranostic for the Neurotensin Receptor 1 (NTSR1) Imaging Shows Targeted Uptake In: NTSR1 is an attractive oncology target CRC and PDAC patients ■ Validated cancer biomarker associated with carcinogenesis of several types of solid tumors ■ High expression, similar to
Slide 7: FPI-2059 - A Novel Small Molecule TAT
FPI-2059 - A Novel Small Molecule TAT Pancreatic Ductal Adenocarcinoma 225 Ac IPN 1087 Shows Single Dose Tumor IPN-1087 proven ability to deliver Kill In Preclinical Models radiometals to tumors in multiple cancer types makes it a promising candidate for 225 targeted alpha therapy with Ac 225 Precli
Slide 8: FPI-2059 Development Strategy and Timeline
FPI-2059 Development Strategy and Timeline 2021 1H 2022 Rapid development of IPN- 225 1087 as an Ac-labeled TAT IND Filing Cohort Expansion Accelerated completion Opportunity of requisite preclinical studies Leverage FPI-1434 225 with Ac labeled IPN-1087 Imaging has shown experience to submit IND (F
Slide 9: FPI-2059 Multiple Market Opportunities
FPI-2059 Multiple Market Opportunities Pancreatic Cancer (PDAC) Colorectal Cancer (CRC) Prostate Cancer 1 58K new patients annually (US+EU5) Opportunities to improve current SoC Radiopharmaceuticals are across all lines of metastatic disease showing increasing utility Typically treated with surgery,
Slide 10: Deal Terms
Deal Terms Fusion will issue to Ipsen: ■ 400,000 shares of its common stock upon closing ■ 200,000 shares upon a patent-related milestone Fusion will pay up to €67.5 million upon the achievement of certain development and regulatory milestones; low single digit royalties on potential future net sale
Slide 11: IPN-1087 Enhances Fusion's Growing Pipeline of TATs
IPN-1087 Enhances Fusion’s Growing Pipeline of TATs Early Radiopharma Preclinical Fusion Programs Phase 1 Phase 2 Phase 3 Discovery Optimization Development FPI-1434 Solid Tumors Expressing IGF-1R FPI-1966 Head & Neck and Bladder Cancers Expressing FGFR3 FPI-2059 (IPN-1087) Solid Tumors Expressing N
Slide 12: Thank You
Thank You www.FusionPharma.com Copyright © 2020 Fusion Pharmaceuticals Inc. All Rights ReservedThank You www.FusionPharma.com Copyright © 2020 Fusion Pharmaceuticals Inc. All Rights Reserved
Fusion Pharmaceuticals — Corporate Update (March 2021) on 6ix